Please provide your email address to receive an email when new articles are posted on . The Alport Syndrome Foundation is accecpting applications from Alport Syndrome patients for the Paul Silver ...

There are various methods of identifying whether a patient has Alport syndrome. The syndrome presents in significant ways in some patients but with less obvious symptoms in other patients, and there ...

There are various treatments that are used to help patients with Alport syndrome to manage their condition. Most of them are used to help reduce and slow down symptoms. The benefits of the treatments ...

In late February, the US Food and Drug Administration (FDA) declined to grant marketing approval to the novel agent bardoxolone methyl as a treatment for Alport syndrome, which means this rare genetic ...

Can treatment delay end-stage renal disease in children with Alport syndrome? New guidelines have been provided based on our ability to identify individuals at risk of early-onset renal failure and on ...

Alport syndrome is a progressive hereditary kidney disease with no definitive therapy. It is caused by mutations in any of the collagen IV genes (COL4A3, COL4A4, and COL4A5). Researchers in Japan, ...

A large-scale analysis of the clinical characteristics of Alport syndrome in Japanese patients has revealed that the effectiveness of existing treatment with ACE inhibitors and/or angiotensin receptor ...

kidney cross section The Committee voted “no on the question of whether the provided evidence demonstrated that bardoxolone is effective in slowing the progression of CKD in patients with Alport ...

Statistically Significant Improvement in Kidney Function Maintained in Alport Syndrome Patients After 48 Weeks of Treatment Statistically Significant Retained Benefit of 4.1 mL/min in Alport Syndrome ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the Alport syndrome market. The report includes a detailed analysis of the pipeline molecules under ...

BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport ...